Technology & Applications
Direct DNA Therapeutics
DNA as the active pharmaceutical ingredient for vaccinations and therapeutics is enabling rapid, versatile, stable, targeted and cost-effective therapies
Therapeutic DNA vaccines
Expression of an antigen via direct administration of DNA in order to elicit an immune response to a pathogen or tumour marker.
Prophylactic DNA vaccines
Expression of an antigen via direct administration of DNA in order to elicit a preventative immune response to infectious disease.
DNA monoclonal antibodies
Direct DNA administration to express a monoclonal antibody (mAb) that binds disease targets of therapeutic importance.
Non-viral gene therapies
Direct administration of DNA to correct diseases caused by faulty gene expression.
Advantages of dbDNA™
dbDNA™ constructs are an optimal active pharmaceutical ingredient for the next generation of direct DNA therapeutics. Key benefits of dbDNA™ include:
Unprecedented yield, unlimited scalability These therapies require large quantities of DNA for development and ultimate commercialization. Our technology can cost-effectively meet the scale of DNA required for all stages of the product life-cycle.
Amplifies complicated secondary structures and repetitive sequences Enables manufacture of DNA sequences that are currently difficult or impossible to manufacture as plasmids, including hairpins, AAV ITRs, mRNA polyA.
No antibiotic resistance genes or bacterial sequences Our acellular process eliminates non-target bacterial sequences such as antibiotic resistance genes that are perceived negatively by regulatory authorities.
Error rate of < 1/107 Our process has a sequence fidelity that easily meets regulatory requirements.